Ftse Mib
34.490,71
0,07%
DAX
18.693,37
0,04%
S&P 500
5.304,72
0,70%
NASDAQ
16.920,79
1,10%
Bitcoin
68.903,15
-0,53%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Neumora Therapeutics Inc (NMRA) Neumora Therapeutics Inc (NMRA) Notizie

NMRA

Neumora Therapeutics (NMRA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NMRA
DataOraFonteTitoloSimboloCompagnia
14/05/202413:00GlobeNewswire Inc.Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar DepressionNASDAQ:NMRANeumora Therapeutics Inc
07/05/202422:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NMRANeumora Therapeutics Inc
07/05/202413:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NMRANeumora Therapeutics Inc
07/05/202413:00GlobeNewswire Inc.Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:NMRANeumora Therapeutics Inc
06/05/202413:00GlobeNewswire Inc.Neumora Therapeutics to Participate in Upcoming Conferences in MayNASDAQ:NMRANeumora Therapeutics Inc
15/04/202412:30GlobeNewswire Inc.Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 StudyNASDAQ:NMRANeumora Therapeutics Inc
13/03/202412:00GlobeNewswire Inc.Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS DaysNASDAQ:NMRANeumora Therapeutics Inc
07/03/202422:34Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NMRANeumora Therapeutics Inc
07/03/202413:00GlobeNewswire Inc.Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:NMRANeumora Therapeutics Inc
16/02/202422:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NMRANeumora Therapeutics Inc
22/01/202413:00GlobeNewswire Inc.Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial OfficerNASDAQ:NMRANeumora Therapeutics Inc
02/01/202413:00GlobeNewswire Inc.Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:NMRANeumora Therapeutics Inc
15/12/202323:06Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:NMRANeumora Therapeutics Inc
12/12/202313:00GlobeNewswire Inc.Neumora Therapeutics Appoints Jason Duncan as Chief Legal OfficerNASDAQ:NMRANeumora Therapeutics Inc
27/11/202313:00GlobeNewswire Inc.Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical StudyNASDAQ:NMRANeumora Therapeutics Inc
01/11/202312:00GlobeNewswire Inc.Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:NMRANeumora Therapeutics Inc
30/10/202312:00GlobeNewswire Inc.Neumora Therapeutics to Participate in Upcoming Conferences in NovemberNASDAQ:NMRANeumora Therapeutics Inc
10/10/202313:00GlobeNewswire Inc.Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and DevelopmentNASDAQ:NMRANeumora Therapeutics Inc
20/09/202300:51KR Market News인스타카트, 나스닥 데뷔로 주가는 12% 상승NASDAQ:NMRANeumora Therapeutics Inc
15/09/202302:49GlobeNewswire Inc.Neumora Therapeutics Announces Pricing of Initial Public OfferingNASDAQ:NMRANeumora Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NMRA

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
ENEL
Enel
BIT
TIT
Telecom Italia
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
STMMI
ST Microelectronics
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
TEN
Tenaris
BIT
RACE
Ferrari NV
BIT
SPM
Saipem
BIT
BAMI
Banco BPM
BIT
PRY
Prysmian
BIT
BPE
Bper Banca
BIT
TITR
Telecom Italia
BIT
SRG
Snam
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network